Kornimate/medical-research-clean huggingface dataset:
a study of 68ga-psma-11 pet scans in people with brain tumors

Conditions: High-grade Glioma; Brain Metastases; Brain Metastases, Adult

Summary: the purpose of this study is to find out whether 68ga-psma-11 pet/ct is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/hgg or brain metastases.


Eligibility criteria:
inclusion criteria: * ability to understand and the willingness to sign (or their legally acceptable representative (lar) must sign) a written informed consent document * adults ≥ 18 years old * suspicion for or histologically or cytologically confirmed and previously treated hgg or brain metastases from a primary extracranial malignancy * lesion size ≥ 1 cm (for the lesion to be biopsied) * ecog performance status ≤ 2 (karnofsky ≥ 60%) * planned to undergo biopsy/resection of brain lesion exclusion criteria: * inability to undergo a pet scan (e.g., claustrophobia or noncompatible implant in case pet/mr is performed) * pregnant or nursing female. all women of childbearing potential must have a documented negative serum or urine pregnancy test \<1 week before study. * uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * patients with severe allergy to both iodinated and gadolinium contrast.

Keywords: 68ga-psma-11 high-grade glioma brain metastases 23-382 memorial sloan kettering cancer center
polymorphisms of interleukins, glypican, and human leukocyte antigen genes and treatment response in multiple sclerosis.

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: hla-drb1 \* gene and some genes involved in inflammation and immunity (il-7r, gpc5, ctss) have been linked to risk of ms and the response to treatment with immunomodulators. this research aims to estimate the risk that confers some variations in the sequence of these genes.

genes hla-drb1 \* and some genes involved in inflammation and immunity have been linked to risk of ms and the response to treatment with immunomodulators. the hla-drb1 \* genes have been associated with risk and response to treatment in ms in multiple studies; however, other genes have been controversial. this research aims to estimate the risk for ms that confers some variations in the sequence of il-7r, gpc5, ctss, hla-drb1 genes. furthermore, it seeks to determine whether these gene variants (polymorphisms) are associated with treatment response to immunomodulators. subjects with ms and healthy subjects will be taken to assess the risk for ms. besides the investigators obtain the medical history of relapse to assess response to treatment in accordance with expanded disability status scale (edss) and relapses.

Eligibility criteria:
inclusion criteria for cases: * subjects with multiple sclerosis * 18 and over * edss less than 5 * signed informed consent inclusion criteria for controls: * healthy subjects * 18 and over * signed informed consent exclusion criteria for cases: * mental retardation * withdrawal of consent * no immunomodulatory treatment exclusion criteria for controls: * mental retardation * withdrawal of consent
comparison colon capsule endoscopy vs optical colonoscopy for colorectal cancer screening in familiar-risk population

Conditions: Colorectal Cancer, Genetics of

Summary: the purpose of this study is to determine if the adherence to screening in first grade relatives of patients with ccr is higher than optical colonoscopy.

the purpose of this study is to compare the adherence and effectiveness of colon capsule endoscopy (cce-2) versus conventional colonoscopy to screen first-degree relatives of patients with colorectal cancer.

Eligibility criteria:
inclusion criteria: * asymptomatic first-degree relatives (parents, siblings or children) of crc patients aged less than 60 years or with two or more first-degree relatives of any age. * signing of informed consent. exclusion criteria: * personal history of adenoma or crc. * history of hereditary crc. * chronic inflammatory disease. * presence of digestive symptoms. * patients with swallowing problems (dysphagia). * personal history of gastrointestinal surgery. * enteritis radioactive. * renal failure. * congestive heart failure * allergy or other contraindication to bysacodyl to peg or phosphates. * pregnancy. * suspected bowel obstruction or intestinal strictures or fistulas known. * colectomy. * paralysis with impaired intestinal motility. * any other process that the investigator's discretion to make inadequate participation.
quetiapine efficacy in bipolar depression study

Conditions: Bipolar Depression

Summary: to reassure the clinical study data on seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression


Eligibility criteria:
inclusion criteria: * the patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent * meet dsm-iv-tr criteria for bipolar depression at the time of baseline exclusion criteria: * since this programme intends to describe quetiapine use in routine clinical practice when prescribed as treatment of bipolar depression, there are no programme specific exclusion criteria, other than: or, any of the following is regarded as a criterion for exclusion from the programme: 1. serious or unstable, medical illness. subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history 2. known intolerance for or lack of response to quetiapine, as judged by the investigator

Keywords: bipolar depression quetiapine observational naturalistic
synerfuse spinal fusion and neuromodulation proof of concept study

Conditions: Spinal Fusion; Radiculopathy Lumbar; Chronic Pain

Summary: the purpose of the study is to evaluate the safety and tolerability of drg stimulation when placing a neurostimulator during the same procedure as implantation of spinal fixation with or without interbody cage systems in patients with chronic back and/or leg pain requiring single level spinal fusion.


Eligibility criteria:
inclusion criteria: * indicated for a single level or two level adjacent spinal fusion having back pain and radiculopathy * have been diagnosed with chronic, intractable pain of the lower back and/or leg refractory to conservative therapy for at least 3 of months * at least 6 months since last surgical procedure on the spine * be 21 years of age or older at the time of enrollment * be willing and capable of giving informed consent * be willing and able to comply with study-related requirements exclusion criteria: * any prior spinal fusion at index or adjacent level * pregnant * have a life expectancy of less than 1 year * be concomitantly participating in another clinical study * be involved in an injury claim under current litigation * baseline narcotic use of ≥ 100 mme per day * significant untreated addiction to dependency producing medications * current active implantable medical device * cancer * have osteoporosis * active infection * allergies to system components * age \> 80 * expected need to undergo mri imaging in the future * other significant comorbidities

Keywords: dorsal root ganglion neurostimulation failed back surgery syndrome
a double blind randomised placebo-controlled trial to assess the role of iron repletion in glucose homeostasis.

Conditions: Iron-deficiency; Iron Toxicity; Glucose Metabolism Disorders (Including Diabetes Mellitus); Metabolic Side Effects of Drugs; Metabolic Disorder, Glucose; Safety Issues

Summary: in this study the investigators aim at addressing potential relationships between iron stores and glucose homeostasis. iron (i.e. ferric carboxymaltose) will be perfused to pre-menopausal, iron-deficient non-anaemic women suffering from a chronic fatigue syndrome and parameters related to glucose homeostasis, parameters related to metabolic syndrome and inflammation will be measured before and after the intervention.


Eligibility criteria:
inclusion criteria: * premenopausal women. * negative pregnancy test. * adequate contraception during the study period and for 1 month following study completion. * overt or relative iron deficiency at screening defined as follows: serum ferritin \<50 ng/ml and transferrin saturation \<20%, or serum ferritin \<30 ng/ml. - serum c-reactive protein: \<5 mg/l if not on oral contraception, or \<20 mg/l if use of oral contraception * intolerance to oral iron formulations, or lack of efficacy of oral iron formulations. * minimum total score of 5 on the visual analogic scale of fatigue. * normal levels of vitamin b12 and folic acid at screening. * availability and willingness to complete all study visits and procedures per protocol. * ability to sign an informed consent. exclusion criteria: * age \<18 years. * menopause (defined as an amenorrhea of at least 12 months). * irregularly menstruating women (menstrual cycle outside a range of 24-38 days in duration) or experiencing overt metrorrhagia (simple spotting not being an exclusion criteria). * body mass index \ 30 kg/m2. * diabetes, defined as subjects with hba1c ≥ 6.5 % and/or with fasting blood glucose levels ≥ 7 mmol/l and/or with a history of diabetes and/or by the use of anti-diabetic drugs. * hb level \<117 g/l or known haemoglobinopathy or haemochromatosis. * blood transfusion within the last 12 weeks. * intake of iron preparations 4 weeks prior to screening. * known hypersensitivity to fcm or to any other iron preparation. * suspicion of major depressive disorder based on patient health questionnaire. * known chronic inflammatory disease, including human immunodeficiency virus, hepatitis b or hepatitis c virus infection. * active malignancy. * decreased renal function (estimated glomerular filtration rate using the ckd-epi equation\<60 ml/min/1.73m2). * liver dysfunction (aspartate aminotransferase and alanine aminotransferase \> 3-fold upper limit). * angina (class iv). * asthma. * documented sleep apnoea. * important recent weight loss (\>10% within the past month). * thyroid dysfunction (thyroid stimulating hormone \>4 µu/ml). * reported weekly alcohol consumption \> 14 standard drinks. * drug abuse (any drug consumption reported in the past 12 months).

Keywords: metabolomics, transcriptomics, ironomics
spinal manipulation and spinal mobilization effects in participants with and without back pain

Conditions: Back Pain

Summary: the objective of the present study is to compare the neuromechanical responses to spinal manipulation and spinal mobilization in participants with chronic nonspecific middle back pain.

although evidences suggest a similar effectiveness of spinal manipulation and spinal mobilization, there is no study that compares the neuromechanical effects of these manual therapies in a experimental context and with the standardization of both interventions. therefore, the objective of the present study is to compare the neuromechanical responses to spinal manipulation (low-amplitude and high-velocity dynamic thrust) and spinal mobilization (repetitions of a low-amplitude and low-velocity nonthrust movement) in participants with and without chronic nonspecific back pain.

Eligibility criteria:
inclusion criteria: * presenting or not a history of chronic nonspecific back pain exclusion criteria: * history of back trauma or surgery * severe osteoarthritis * inflammatory arthritis * vascular conditions * contraindication to the use of spinal manipulation or spinal mobilization * pregnancy * scoliosis

Keywords: spinal manipulation spinal mobilization spinal stiffness
shared decision making in long-term care facilities

Conditions: Dementia

Summary: shared decision making (sdm) is defined as a process where healthcare professionals and patients make decisions together, using the best available evidence. sdm, as a communication and decision method, can be used also with persons suffering from dementia. yet, sdm with persons with dementia or even with their family caregivers is not widespread. the present research project aims to develop and evaluate an sdm framework in care planning to be implemented in long-term care facilities, in order to obtain a constantly developing care plan that focuses not only on the medical, physical, psychosocial and spiritual needs of the resident, but that considers and documents his preferences and the actions taken by caregivers to meet them. the current project is a controlled exploratory study. case studies that involve a triad in each case, composed by the resident with moderate or severe dementia, his family caregiver and the professional usually taking care for the resident, will be used (n=16 professionals; n=40 residents; n=40 family caregivers). professional caregivers of two nursing homes, one located in italy and one in the netherlands, will receive a specific training in sdm principles and will guide the sdm interview within the triad. primary outcome will be the proportion of residents whose preferences and needs, together with the related actions to meet them, are known, documented and satisfied in their 'life-and-care plans'. secondary outcomes are the residents' and family caregivers' quality of life; the family caregivers' sense of competence and the healthcare professionals' job satisfaction. semi-structured interviews and focus group interviews will be performed to assess satisfaction with the intervention and barriers and facilitators to its implementation. assessments are performed at baseline and six months after the intervention. we hypothesize that the use of the sdm process in care planning will increase the number of met needs and will improve the residents' and family caregivers quality of life, the family caregivers' sense of competence and the healthcare professionals' job satisfaction. the key element of this study is that it will contribute to our knowledge about the efficacy and feasibility of an sdm framework in care planning in long-term care facilities with persons with moderate to severe dementia.


Eligibility criteria:
inclusion criteria: * diagnosis of dementia based on the diagnostic and statistical manual of mental disorders (dsm) iv * from moderate to severe cognitive decline (global deterioration scale from 4 to 6) * supported by a family caregiver who can be involved exclusion criteria: * unable to pronounce simple sentences

Keywords: shared decision making dementia long-term care nursing home care plan
doxycycline for lateral epicondylalgia - rct

Conditions: Lateral Epicondylalgia (Tennis Elbow)

Summary: matrix metalloproteinases are involved in the pathogenesis of tendinopathy. doxycycline, a widely available pharmaceutical agent mostly used for its antibiotic properties, also functions as an inhibitor of mmps. this study aims to investigate the effect of doxycycline treatment on lateral epicondylalgia (tennis elbow). during three weeks, patients receive doxycycline tablets 100 mg twice daily, or placebo. main outcome variable is pain (vas) at three weeks. serum and/or plasma levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases are measured.


Eligibility criteria:
inclusion criteria: * age 18-65 * pain at the lateral side of the elbow ≥8 weeks * local tenderness on palpation of the lateral epicondyle * pain on resisted extension of the wrist exclusion criteria: * rheumatic disorder * history of fibromyalgia or generalised pain * elbow surgery (on the painful side) * active infection * glucocorticoid treatment during the duration of symtoms of epicondylalgia * nsaid use within 1 w before presentation and during the study * pregnancy * taking drug that might interact with doxycycline

Keywords: tendinopathy tennis elbow lateral epicondylitis lateral epicondylalgia mmp-inhibitor
multimodal noninvasive assessment of peripheral circulation in chronic limb-threatening ischemia

Conditions: Chronic Limb Threatening Ischemia

Summary: assessment of a novel diagnostic method for screening and diagnosing chronic limb-threatening ischemia (clti). using hyperspectral and thermal imaging, the perfusion and oxygenation in the lower limbs will be studied in healthy and unhealthy individuals.


Eligibility criteria:
inclusion criteria: * for clti patients age \>50 * for age control group age \>50 and not diagnosed with cardiovascular diseases. 0.9 \< abi \< 1.3 * for healthy group 18 \<= age \<= 50 and no history of cardiovascular disease * volunteering for study exclusion criteria: * inability to give informed consent * denial

Keywords: hyperspectral imaging thermal imaging angiosomes clti diabetes
a 52-week, placebo-controlled study to evaluate the efficacy and safety of 2 doses of chf6001 dpi (tanimilast), as add-on to maintenance triple therapy in subjects with copd and chronic bronchitis (pilaster)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of the study is to evaluate the efficacy and safety of two doses of chf6001 (tanimilast), as add-on to maintenance triple therapy in the target patient population.


Eligibility criteria:
inclusion criteria: * adults aged ≥ 40 years with copd and chronic bronchitis * current or ex-smokers (history ≥ 10 pack years). * post-bronchodilator fev1 \<60% of the subject predicted normal value and fev1/fvc ratio \< 0.7. * at least, one moderate or severe copd exacerbation in previous year. * cat score ≥ 10 * subjects on regular maintenance triple therapy for at least 12 months prior to screening and receiving regular maintenance triple therapy for at least 3 months prior to screening visit exclusion criteria: * subjects with current asthma. * subjects with moderate or severe copd exacerbation 4 weeks prior to study entry and randomization. * subjects with known α-1 antitrypsin deficiency as the underlying cause of copd. * subjects with copd emphysema or mixed phenotypes. * subjects with known respiratory disorders other than copd. * subjects with active cancer or a history of lung cancer with full recovery less than 1 year after completing cancer therapy. * subjects under roflumilast treatment within 6 months before study entry. * subjects with a diagnosis of depression, generalised anxiety disorder, suicidal ideation. * subjects with clinically significant cardiovascular. * subjects with a significant neurological disease. * subjects with clinically significant laboratory abnormalities. * subjects with moderate or severe hepatic impairment

Keywords: copd chronic bronchitis pde4 inhibitor anti-inflammatory respiratory drug tanimilast
evaluation of pétale® (small hearing test equipment for children) for the screening of hearing disorders in children from 9 months to 3 years old by the general practitioner or pediatrician

Conditions: Petale; Hearing Disorders; Child Development

Summary: the aim of this study is to confirm the value of this new version of pétale® ((small equipment for testing the child's hearing) in the daily practice of general practitioners or pediatricians for the screening of hearing disorders in very young children.

the research procedure is auditory stimulation using pétale® (small equipment for testing the child's hearing) based on the "orientation reflex" ("ewing" test): the child is seated on the companion's knees between the two enclosures and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.

Eligibility criteria:
inclusion criteria: * chil, girl or boy between 9 months and 3 years-old * child seen in consultation by a general practitioner or a pediatrician whatever the reason for consultation * child attached to a beneficiary of a social security scheme * signature of informed consent by parents. exclusion criteria: * age greater than 3 years and less than 9 months * refusal of one or more parents during the consultation * state of the child which does not allow the screening test to be carried out
cervical cord to canal diameter ratio

Conditions: Cervical Pain

Summary: cervical epidural block could cause spinal cord injury if the epidural needle is over-inserted and punctures the spinal cord. investigators retrospectively evaluated the imaging data of 100 patients (50 men and 50 women) who underwent both cervical computed tomography (ct) and cervical magnetic resonance imaging (mri) at our hospital. investigators measured the diameters of the spinal canal and spinal cord from the 3rd cervical vertebra to the 1st thoracic vertebra (t1) at each level by using the patients' cervical ct and mr images. the spinal cord and spinal canal diameters were measured in the transverse plane of cervical mr and ct images, respectively.

the spinal canal diameter, i.e., the epidural transverse diameter, was measured as the distance between the innermost border of the left and right pedicles at each upper pedicular level from c3 to t1 on transverse ct images by using a picture archiving and communication system (pacs; infinitt pacs g3, infinitt healthcare, korea) the spinal cord diameter was measured between the left and right outermost distances of the cord at each upper pedicular level, which were almost the same locations used for measuring the spinal canal diameter, from c3 to t1 on transverse mr images by using the pacs.

Eligibility criteria:
inclusion criteria: * 100 patients (50 men and 50 women aged 20 to 70 years old) who visited our hospital and underwent both cervical ct and mri simultaneously exclusion criteria: * patients who had a history of cervical spine surgery or cervical cord edema, whose ct or mr images did not include all the cervical vertebrae from c3 to t1, * patients who had at least one missing medical detail such as diagnosis, age, height, or weight.

Keywords: coronal cervical canal diameter cervical cord diameter
effect of shoulder symptom modification procedure (ssmp) in managing patients with frozen shoulder

Conditions: Frozen Shoulder

Summary: the study is about intervention to patient with frozen shoulder to help patients improve function and shoulder disability , reduce pain and improve range of motion, the main aim of this study is to find out which treatment intervention ssmp , mwm and sham mobilization give effective results


Eligibility criteria:
inclusion criteria: * • diagnosis of adhesive capsulitis confirmed by a healthcare professional. * scores more than 2 in adhesive capsulitis scale * range of motion affected in capsular pattern * age between 40-65 years. * willingness to participate by signing informed consent exclusion criteria: * having any history of shoulder dislocation * humerus fractures or trauma * diagnosed with any sort of cancer * history of cardiovascular disease

Keywords: ssmp mwm sham mobilization frozen shoulder